ClinicalTrials.gg
Sign In
Status unknownNCT02770677Updated Aug 16, 2019

Modified Dantien Salee Yoga Training Program in Chronic Obstructive Pulmonary Disease Rehabilitation

An interventional study of Modified Dantien Salee Yoga Training Program in Pulmonary Disease, Chronic Obstructive, sponsored by Mahidol University. Status unknown at 1 site in Thailand. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-08-16.

Sponsored by Mahidol University · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Aug 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

COPD patients will be recruited and assigned into one of each group: 1) Control group or 2) Yoga group. In Yoga groups, subjected will be asked to participate in Modified Dantien Yoga training for 12 weeks (3 times/week, 60 min/time). The subjects will be evaluated their pulmonary function, functional fitness performance, dyspnea score, and quality of life at baseline and after 12 wk training.

02

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Yoga
  • COPD
  • rehabilitation
03

In context

Pulmonary Disease, Chronic Obstructive

4,253 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 707 are open to participants now.

This study's planned enrollment of 12 is below the median of 70 across 3,008 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Mahidol University is the lead sponsor of 744 studies on the registry; 116 are open to participants now.

Browse Mahidol University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Stable COPD patients > or equal 6 weeks.
  2. Age > or equal 50-80 years.
  3. FEV1 > or equal 30% predicted after take bronchodilators drug.
  4. Resting SpO2 > or equal 90% room air.
  5. Did not pulmonary rehabilitation program before start the yoga

Exclusion criteria

Exclusion Criteria:

  1. Subjects with musculoskeletal disorders, mental and neurological disorders, and acute coronary heart disease.
  2. Blood Pressure (systolic) > 180 mmHg.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • No intervention
    Control group

    Control group will be asked to continue their normal daily life without Yoga training

  • Experimental
    Yoga group

    Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks

    Other: Modified Dantien Salee Yoga Training Program

Interventions

  • OtherModified Dantien Salee Yoga Training Program

    The intervention aims to improve pulmonary function and functional fitness.

06

What researchers measure

Primary outcomes

  1. Change from baseline FVC (Forced Vital Capacity) (L) at 12 weeks

    Change of FVC (Forced Vital Capacity) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  2. Change from baseline FEV1 (Forced Expiratory Volume in 1 minute)(L) at 12 weeks

    Change of Forced Expiratory Volume in 1 second will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  3. Change from baseline TLC (Total Lung Capacity) (L) at 12 weeks

    Change of TLC (Total Lung Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  4. Change from baseline FRC (Functional Residual Capacity) (L) at 12 weeks

    Change of FRC (Functional Residual Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  5. Change from baseline IC (Inspiratoy Capacity) (L) at 12 weeks

    Change of IC (Inspiratoy Capacity) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  6. Change from baseline RV (Residual Volume) (L) at 12 weeks

    Change of RV (Residual Volume) (L) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  7. Change from baseline MVV (Maximum Voluntary Ventilation) (L/min) at 12 weeks

    Change of MVV (Maximum Voluntary Ventilation) (L/min) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  8. Change from baseline PEFR (Peak Expiratory Flow Rate) (L/sec) at 12 weeks

    Change of MVV (Maximum Voluntary Ventilation) (L/sec) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  9. Change from baseline DLCO (Diffusion capacity to carbon monoxide) (ml/mmHg/min) at 12 weeks

    Change of DLCO (Diffusion capacity to carbon monoxide) (ml/mmHg/min) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  10. Change from baseline PI max (Maximal Inspiratoy Pressure) (cm H2O) at 12 weeks

    Change of PI max (Maximal Inspiratoy Pressure) (cm H2O) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  11. Change from baseline PE max (Maximal Expiratoy Pressure) (cm H2O) at 12 weeks

    Change of PE max (Maximal Expiratoy Pressure) (cm H2O) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  12. Change from baseline FEV1/FVC % predicted at 12 weeks

    Change of FEV1/FVC % Predicted (Percent Predicted of ratio of FEV1 and FVC) (% predicted) will be measured on a computerized Spirometer at the baseline and 12 weeks.

    Time frame: 12 weeks

  13. Change from baseline lower body strength assessed with Chair Standing test at 12 weeks

    Change from baseline lower body strength assessed with Chair standing test. ( time/30 sec)

    Time frame: 12 weeks

  14. Change from baseline upper body strength assessed with Arm curl test at 12 weeks

    Change from baseline upper body strength assessed with Arm curl test (time/30 sec)

    Time frame: 12 weeks

  15. Change from baseline lower body flexibility assessed with Chair Sit and Reach test at 12 weeks

    Change from baseline lower body flexibility assessed with Chair Sit and Reach test (cm)

    Time frame: 12 weeks

  16. Change from baseline upper body flexibility assessed with Back Scratch test at 12 weeks

    Change from baseline upper body flexibility assessed with Back Scratch test (cm)

    Time frame: 12 weeks.

  17. Change from baseline agility/dynamic balance assessed with 8-foot Up and Go test at 12 weeks

    Change from baseline agility/dynamic balance assessed with 8-foot Up and Go test (sec)

    Time frame: 12 weeks

  18. Change from baseline Exercise Capacity assessed with 6-minute walk test at 12 weeks

    Change from baseline Exercise Capacity assessed with 6-minute walk test (meter)

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline Dyspnea score assessed with visual analog scale at 12 weeks

    Dyspnea or shortness of breath will be measured by visual analog scale (VAS) 1-10 point scale at the baseline and 12 weeks.

    Time frame: 12 weeks

  2. Change from baseline Quality of life score assessed with St. George's respiratory Questionnaires (SGRQ) at 12 weeks.

    Change from baseline Quality of Life score assessed with St. George's respiratory Questionnaires (SGRQ) in Thai version at 12 weeks.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine, Siriraj Hospital
    Bangkoknoi, Bangkok 10700, Thailand
    • Arth Nana, MD · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2016 (actual). Primary completion is estimated for Oct 2019, 42 months after the start.

Of 796 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 42 months is above that.

Counting every sponsor, half of 848 studies reached it within 24 months; a quarter within 11 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2016
First posted
May 12, 2016
StartActual
Apr 7, 2016
Primary completionEst.
Oct 30, 2019
CompletionEst.
Oct 30, 2019
Last update
Aug 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02770677
Lead sponsor
Mahidol University
Responsible party
Duangjun Phantayuth (Assistant Professor, Mahidol University) — Principal investigator
First posted
May 12, 2016
Start date
Apr 7, 2016
Primary completion
Oct 30, 2019 (estimated)
Completion
Oct 30, 2019 (estimated)
Last update
Aug 16, 2019

Study contacts

Duangjun Phantayuth, M.Sc.
Contact
leksalaya@yahoo.com
6624414295 ext. 311
Amornpan Ajjimaporn, Ph.D
study chair · Mahidol

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary Disease, Chronic Obstructive →

Other studies from this sponsor

Mahidol University →

Start the discussion